RAPIDe-3 In partnership with about 75 other institutions across the globe, the practice of Dr. Raffi Tachdjian is currently participating in the RAPIDe-3 study on hereditary angioedema (HAE) type 1 and type 2. The purpose of this study is to evaluate the efficacy and safety of an oral investigational drug,…
Sponsored Content
Recent Posts
- Dawnzera wins approval in EU as preventive treatment for HAE
- Preparing for an internet or power outage is crucial with angioedema
- A caregiver’s role when facing the ‘boss levels’ of HAE
- Guest Voice: In my big family, I’m not alone with HAE
- Ekterly provides early relief in laryngeal and abdominal HAE attacks